Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

that the duration of the semaglutide compounding opportunity may be shorter than some expected.” The firm, which thinks there is “less likelihood of material upside revisions to 2025 revenue ...